GENIX PHARMACEUTICALS CORP (GENX.CA) Fundamental Analysis & Valuation
TSX-V:GENX • CA37232A1093
Current stock price
0.02 CAD
0 (0%)
Last:
This GENX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. GENX.CA Profitability Analysis
1.1 Basic Checks
- GENX had negative earnings in the past year.
- GENX had a negative operating cash flow in the past year.
- In the past 5 years GENX always reported negative net income.
- GENX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -327.68%, GENX is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.68% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-717.5%
ROA(5y)-440.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- GENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. GENX.CA Health Analysis
2.1 Basic Checks
- GENX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- GENX has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for GENX has been increased compared to 5 years ago.
- Compared to 1 year ago, GENX has a worse debt to assets ratio.
2.2 Solvency
- GENX has an Altman-Z score of -664.39. This is a bad value and indicates that GENX is not financially healthy and even has some risk of bankruptcy.
- GENX has a worse Altman-Z score (-664.39) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -664.39 |
ROIC/WACCN/A
WACC6.21%
2.3 Liquidity
- GENX has a Current Ratio of 0.01. This is a bad value and indicates that GENX is not financially healthy enough and could expect problems in meeting its short term obligations.
- GENX has a Current ratio of 0.01. This is in the lower half of the industry: GENX underperforms 66.67% of its industry peers.
- GENX has a Quick Ratio of 0.01. This is a bad value and indicates that GENX is not financially healthy enough and could expect problems in meeting its short term obligations.
- GENX has a Quick ratio of 0.01. This is in the lower half of the industry: GENX underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.01 | ||
| Quick Ratio | 0.01 |
3. GENX.CA Growth Analysis
3.1 Past
- GENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.78%, which is quite impressive.
- GENX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.50%.
- Measured over the past years, GENX shows a very negative growth in Revenue. The Revenue has been decreasing by -50.46% on average per year.
EPS 1Y (TTM)97.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-97.5%
Revenue growth 3YN/A
Revenue growth 5Y-50.46%
Sales Q2Q%-100%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. GENX.CA Valuation Analysis
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. GENX.CA Dividend Analysis
5.1 Amount
- No dividends for GENX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GENX.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:GENX (3/5/2026, 7:00:00 PM)
0.02
0 (0%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners32.37%
Ins Owner ChangeN/A
Market Cap1.22M
Revenue(TTM)100
Net Income(TTM)-88.80K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12244 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.68% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-717.5%
ROA(5y)-440.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.01 | ||
| Quick Ratio | 0.01 | ||
| Altman-Z | -664.39 |
F-Score2
WACC6.21%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.5%
Revenue growth 3YN/A
Revenue growth 5Y-50.46%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.35%
OCF growth 3YN/A
OCF growth 5YN/A
GENIX PHARMACEUTICALS CORP / GENX.CA Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for GENIX PHARMACEUTICALS CORP?
ChartMill assigns a fundamental rating of 0 / 10 to GENX.CA.
Can you provide the valuation status for GENIX PHARMACEUTICALS CORP?
ChartMill assigns a valuation rating of 0 / 10 to GENIX PHARMACEUTICALS CORP (GENX.CA). This can be considered as Overvalued.
What is the profitability of GENX stock?
GENIX PHARMACEUTICALS CORP (GENX.CA) has a profitability rating of 0 / 10.